Table 5.
Pharmacokinetic parameters of ritonavir (RTV) in rats (n = 6).
| Formulations | AUC0-t * (mg × h/L) | T1/2 (h) | Cmax (ng/mL) | Frel (%) a | Frel (%) b |
|---|---|---|---|---|---|
| LPV/RTV NP | 1.05 ± 0.10 | 13.12 ± 0.52 | 203.54 ± 31.95 | 415.57 ± 95.67 | 239.90 ± 42.08 |
| RTV NP | 0.59 ± 0.06 | 12.38 ± 4.37 | 87.01 ± 7.90Δ | 230.90 ± 44.25 | 134.71 ± 28.75 |
| Kaletra® | 0.45 ± 0.10 | 9.02 ± 1.22 | 58.73 ± 15.32 | / | / |
| RTV raw drug | 0.26 ± 0.04 | 13.85 ± 4.89 | 24.10 ± 3.85 | / | / |
RTV: ritonavir; NP: nanoparticle
Δ
No significant difference in Cmax between the RTV NP and the commercial product (Kaletra®) (P > 0.05) while significant difference (P < 0.05) was observed when comparing all other testing groups.
*
Significant difference in AUC0-t was observed when comparing all testing groups (P < 0.05).
a
calculated based on AUC0-t by comparing to the RTV raw drug
b
calculated based on AUC0-t by comparing to Kaletra®